Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AGA Medical expands Amplatzer line

This article was originally published in The Gray Sheet

Executive Summary

Firm launches Amplatzer Muscular VSD Occluder for closure of complex ventricular septal defects following PMA approval Sept. 7. The device, which is placed via a transcatheter procedure in patients at high risk for surgical closure, is the latest addition to AGA's Amplatzer line. Also available in the United States are the Amplatzer septal occluder for atrial septal defects, and the Amplatzer duct occluder for closure of patent ductus arteriosus defects. The firm also offers vascular plugs ("1The Gray Sheet" Sept. 3, 2007, p. 11)

You may also be interested in...

AGA Medical’s Pipeline Diversifies Into Vascular Space

AGA Medical, a maker of minimally invasive devices to treat heart defects, is expanding its product portfolio further into the vascular space

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts